Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Harmony Biosciences Holdings ( (HRMY) ) has shared an update.
On September 24, 2025, Harmony Biosciences announced that its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome did not meet its primary endpoint due to a higher than expected placebo response rate. Despite this, the company remains committed to analyzing the data for insights and continuing its development of therapies for rare neurological conditions, with plans to initiate Phase 3 trials for other programs later this year.
The most recent analyst rating on (HRMY) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.
Spark’s Take on HRMY Stock
According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.
Harmony Biosciences’ overall stock score is driven by its strong financial performance and positive earnings call, highlighting robust revenue growth and a promising clinical pipeline. However, technical analysis indicates bearish momentum, which tempers the overall score. The stock appears undervalued based on its P/E ratio, but the lack of a dividend yield is a minor drawback.
To see Spark’s full report on HRMY stock, click here.
More about Harmony Biosciences Holdings
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., the company is committed to advancing therapeutic innovations and fostering community programs.
Average Trading Volume: 704,598
Technical Sentiment Signal: Sell
Current Market Cap: $1.54B
Learn more about HRMY stock on TipRanks’ Stock Analysis page.